BiomX raises $12M in combined offerings; funds BX004 Phase 2b to Q1 2026

BiomX Inc.

Gross proceeds ~$12M from registered direct offering, private placement, and warrant exercise at $0.9306/share.
Investors include Deerfield Management, Cystic Fibrosis Foundation, and Nantahala Capital.
Proceeds to fund BX004 Phase 2b in CF; topline results expected Q1 2026.
Existing warrants reduced from $2.311 to $0.9306; new warrants issued for 100% of exercised shares.
Also advancing BX211 Phase 2 readout in diabetic foot osteomyelitis this quarter.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.